Intellia Therapeutics Inc (NTLA) Shares Decline Despite Market Challenges

TEAM

The stock price of Intellia Therapeutics Inc (NASDAQ: NTLA) has plunged by -5.42 when compared to previous closing price of 12.17, but the company has seen a 7.57% gain in its stock price over the last five trading sessions. accessnewswire.com reported 2025-02-24 that NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=131935&wire=1 or contact Joseph E. Levi, Esq.

Is It Worth Investing in Intellia Therapeutics Inc (NASDAQ: NTLA) Right Now?

NTLA has 36-month beta value of 1.95. Analysts have mixed views on the stock, with 17 analysts rating it as a “buy,” 4 as “overweight,” 7 as “hold,” and 0 as “sell.”

The public float for NTLA is 96.20M, and currently, short sellers hold a 25.01% ratio of that float. The average trading volume of NTLA on February 25, 2025 was 2.86M shares.

NTLA’s Market Performance

NTLA’s stock has seen a 7.57% increase for the week, with a 1.95% rise in the past month and a -18.54% fall in the past quarter. The volatility ratio for the week is 8.45%, and the volatility levels for the past 30 days are at 6.80% for Intellia Therapeutics Inc The simple moving average for the last 20 days is 9.89% for NTLA stock, with a simple moving average of -38.51% for the last 200 days.

Analysts’ Opinion of NTLA

Many brokerage firms have already submitted their reports for NTLA stocks, with Morgan Stanley repeating the rating for NTLA by listing it as a “Equal-Weight.” The predicted price for NTLA in the upcoming period, according to Morgan Stanley is $11 based on the research report published on January 27, 2025 of the current year 2025.

Goldman, on the other hand, stated in their research note that they expect to see NTLA reach a price target of $32, previously predicting the price at $136. The rating they have provided for NTLA stocks is “Neutral” according to the report published on February 23rd, 2024.

NTLA Trading at 2.34% from the 50-Day Moving Average

After a stumble in the market that brought NTLA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.99% of loss for the given period.

Volatility was left at 6.80%, however, over the last 30 days, the volatility rate increased by 8.45%, as shares surge +4.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.27% lower at present.

During the last 5 trading sessions, NTLA rose by +7.57%, which changed the moving average for the period of 200-days by -51.48% in comparison to the 20-day moving average, which settled at $10.47. In addition, Intellia Therapeutics Inc saw -1.29% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at NTLA starting from Bhanji Muna, who sale 265 shares at the price of $9.97 back on Jan 29 ’25. After this action, Bhanji Muna now owns 19,468 shares of Intellia Therapeutics Inc, valued at $2,642 using the latest closing price.

Dube Michael P, the VP, Chief Accounting Officer of Intellia Therapeutics Inc, sale 1,372 shares at $12.18 during a trade that took place back on Jan 03 ’25, which means that Dube Michael P is holding 45,640 shares at $16,711 based on the most recent closing price.

Stock Fundamentals for NTLA

Current profitability levels for the company are sitting at:

  • -12.48 for the present operating margin
  • 0.82 for the gross margin

The net margin for Intellia Therapeutics Inc stands at -12.12. The total capital return value is set at -0.5. Equity return is now at value -52.23, with -43.22 for asset returns.

Based on Intellia Therapeutics Inc (NTLA), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -3.51. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is -60.88.

Currently, EBITDA for the company is -506.31 million with net debt to EBITDA at 0.04. When we switch over and look at the enterprise to sales, we see a ratio of 26.77. The receivables turnover for the company is 4.87for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.73.

Conclusion

To put it simply, Intellia Therapeutics Inc (NTLA) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts